个体化治疗软件对乳腺癌术后辅助化疗有效性的验证研究(3)
 |
| 第1页 |
参见附件(3034KB，3页)。
[5]Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer [J]. J Clin Oncol,2007,25(1):118-145.
[6]Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with six months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from NSABP B-15 [J]. Journal of Clinical Oncology,1990,8(9):1483-1496.
[7]Azambuja E, Paesmans M, Bernard-Marty C, et al. Phase Ⅲ trial comparing two dose levels of epirubicin combined with cyclophosphamide (EC or HEC) with cyclophosphamide, methotrexate, and fluorouracil (CMF) in 777 women with node-positive (N+) breast cancer (BC):10-year follow-up results [J]. J Clin Oncol,2006,24(18):568.
[8]Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer [J]. N Engl J Med,2005,352(22):2302-2313.
[9]Goldhirsch A, Colleoni M, Coates AS, et al. Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer Study Group (IBCSG) [J]. Ann Oncol,1998,9(5):489-493.
[10]Goldhirsch A, Ingle JN, Gelber RD, et al. Threshold for therapies: highlights of the Sankt Gallen international expert consensus on the primary therapy of early breast cancer [J]. Ann Oncol,2009,20(8):1319-1329.
[11]Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer [J] ......
您现在查看是摘要介绍页，详见PDF附件(3034KB，3页)。